The first-generation BTK inhibitor ibrutinib was first approved in the US for MCL treatment in 2013 [8] and is now also indicated for use in patients with CLL, small lymphocytic lymphoma, Waldenström macroglobulinemia, and marginal zone lymphoma [9]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.